BioLineRx BLRX announced today that a recent analysis of the results from the
Phase IIb EAGLE trial for BL-1020, a first in class, orally available,
GABA-enhanced antipsychotic for the treatment of schizophrenia,
indicates that BL-1020 demonstrated a significant increase in efficacy
at improving cognitive impairment associated with this condition, as
compared to the original analysis of the study.
The findings pertain to the results of the Phase IIb EAGLE study, first
published in September 2009, for determining safety, efficacy, and
tolerability of BL-1020 compared to Risperidone, an approved atypical
antipsychotic drug, and placebo. Results of the study showed that
BL-1020 was significantly better than the placebo and comparable with
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in